THE ROLE OF BUTYRIC ACID AS A OPROTECTIVE AGENT AGAINST INFLAMMATORY BOWEL DISEASE

Emanuele Sinagra, Vincenzo Davide Palumbo, Giovanni Tomasello, Danila Di Majo, Angelo Leone, Alida Abruzzo, Attilio Ignazio Lo Monte, Marco Giammanco, Giovanni Cassata, Provvidenza Damiani, Emanuele Sinagra, Luca Cicero, Giovanni Tomasello

Risultato della ricerca: Article

20 Citazioni (Scopus)

Abstract

Inflammatory Bowel disease (IBD), such as Crohn's disease and ulcerative colitis, are pathologies characterized by a chronic inflammation of the gastrointestinal tract. Their etiopathogenesis is not yet fully understood. Immune system and heat shock proteins (HSPs) dysfunctions are considered to be among the most likely causes of these diseases. Butyrate is a short-chain fatty acid produced by intestinal microflora. It has a trophic, benefical and protective role in the colonic mucosa, and it also induces changes in Hsp levels and localization. It may therefore be a valuable complementary therapeutic agent when used alongside trraditional drugs (mesalazine and corticosteroids) to treat the production of butyrate in the endoluminal environment may promote clinical remission in IBD patients. Due to these characteristics, there has been keen interest in the use of butyrate as a novel therapeutic supplement in the recent years. The current findings need to be validated through further clinical trials to better define the bbiomolecular dynamics of butyrate in the colonocytes of IBD patients.
Lingua originaleEnglish
pagine (da-a)24-35
Numero di pagine12
RivistaEuroMediterranean Biomedical Journal
Volume9
Stato di pubblicazionePublished - 2014

Fingerprint

Butyric Acid
Butyrates
Inflammatory Bowel Diseases
Mesalamine
Volatile Fatty Acids
Heat-Shock Proteins
Ulcerative Colitis
Crohn Disease
Gastrointestinal Tract
Immune System
Adrenal Cortex Hormones
Mucous Membrane
Clinical Trials
Pathology
Inflammation
Therapeutics
Pharmaceutical Preparations

All Science Journal Classification (ASJC) codes

  • Medicine(all)

Cita questo

@article{b1a035af23e54ad5b2807a94c63d422f,
title = "THE ROLE OF BUTYRIC ACID AS A OPROTECTIVE AGENT AGAINST INFLAMMATORY BOWEL DISEASE",
abstract = "Inflammatory Bowel disease (IBD), such as Crohn's disease and ulcerative colitis, are pathologies characterized by a chronic inflammation of the gastrointestinal tract. Their etiopathogenesis is not yet fully understood. Immune system and heat shock proteins (HSPs) dysfunctions are considered to be among the most likely causes of these diseases. Butyrate is a short-chain fatty acid produced by intestinal microflora. It has a trophic, benefical and protective role in the colonic mucosa, and it also induces changes in Hsp levels and localization. It may therefore be a valuable complementary therapeutic agent when used alongside trraditional drugs (mesalazine and corticosteroids) to treat the production of butyrate in the endoluminal environment may promote clinical remission in IBD patients. Due to these characteristics, there has been keen interest in the use of butyrate as a novel therapeutic supplement in the recent years. The current findings need to be validated through further clinical trials to better define the bbiomolecular dynamics of butyrate in the colonocytes of IBD patients.",
author = "Emanuele Sinagra and Palumbo, {Vincenzo Davide} and Giovanni Tomasello and {Di Majo}, Danila and Angelo Leone and Alida Abruzzo and {Lo Monte}, {Attilio Ignazio} and Marco Giammanco and Giovanni Cassata and Provvidenza Damiani and Emanuele Sinagra and Luca Cicero and Giovanni Tomasello",
year = "2014",
language = "English",
volume = "9",
pages = "24--35",
journal = "EuroMediterranean Biomedical Journal",
issn = "2279-7165",
publisher = "EuroMediterranean Biomedical Journal",

}

TY - JOUR

T1 - THE ROLE OF BUTYRIC ACID AS A OPROTECTIVE AGENT AGAINST INFLAMMATORY BOWEL DISEASE

AU - Sinagra, Emanuele

AU - Palumbo, Vincenzo Davide

AU - Tomasello, Giovanni

AU - Di Majo, Danila

AU - Leone, Angelo

AU - Abruzzo, Alida

AU - Lo Monte, Attilio Ignazio

AU - Giammanco, Marco

AU - Cassata, Giovanni

AU - Damiani, Provvidenza

AU - Sinagra, Emanuele

AU - Cicero, Luca

AU - Tomasello, Giovanni

PY - 2014

Y1 - 2014

N2 - Inflammatory Bowel disease (IBD), such as Crohn's disease and ulcerative colitis, are pathologies characterized by a chronic inflammation of the gastrointestinal tract. Their etiopathogenesis is not yet fully understood. Immune system and heat shock proteins (HSPs) dysfunctions are considered to be among the most likely causes of these diseases. Butyrate is a short-chain fatty acid produced by intestinal microflora. It has a trophic, benefical and protective role in the colonic mucosa, and it also induces changes in Hsp levels and localization. It may therefore be a valuable complementary therapeutic agent when used alongside trraditional drugs (mesalazine and corticosteroids) to treat the production of butyrate in the endoluminal environment may promote clinical remission in IBD patients. Due to these characteristics, there has been keen interest in the use of butyrate as a novel therapeutic supplement in the recent years. The current findings need to be validated through further clinical trials to better define the bbiomolecular dynamics of butyrate in the colonocytes of IBD patients.

AB - Inflammatory Bowel disease (IBD), such as Crohn's disease and ulcerative colitis, are pathologies characterized by a chronic inflammation of the gastrointestinal tract. Their etiopathogenesis is not yet fully understood. Immune system and heat shock proteins (HSPs) dysfunctions are considered to be among the most likely causes of these diseases. Butyrate is a short-chain fatty acid produced by intestinal microflora. It has a trophic, benefical and protective role in the colonic mucosa, and it also induces changes in Hsp levels and localization. It may therefore be a valuable complementary therapeutic agent when used alongside trraditional drugs (mesalazine and corticosteroids) to treat the production of butyrate in the endoluminal environment may promote clinical remission in IBD patients. Due to these characteristics, there has been keen interest in the use of butyrate as a novel therapeutic supplement in the recent years. The current findings need to be validated through further clinical trials to better define the bbiomolecular dynamics of butyrate in the colonocytes of IBD patients.

UR - http://hdl.handle.net/10447/87223

UR - http://www.embj.org

M3 - Article

VL - 9

SP - 24

EP - 35

JO - EuroMediterranean Biomedical Journal

JF - EuroMediterranean Biomedical Journal

SN - 2279-7165

ER -